Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

Diagnostics companies enter agreement to expand access to blood-based IsoPSA test

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

Study evaluates polygenic risk score for prostate cancer risk prediction

March 18th 2023

FDA approval sought for niraparib/abiraterone tablet for BRCA+ mCRPC

March 1st 2023

UnitedHealthcare will cover Genomic Prostate Score test

February 16th 2023

Diagnostics companies enter agreement to expand access to blood-based IsoPSA test

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

Study evaluates polygenic risk score for prostate cancer risk prediction

March 18th 2023

FDA approval sought for niraparib/abiraterone tablet for BRCA+ mCRPC

March 1st 2023

UnitedHealthcare will cover Genomic Prostate Score test

February 16th 2023

Diagnostics companies enter agreement to expand access to blood-based IsoPSA test

Study evaluates patient experiences with biopsy-based genomic testing during active surveillance

Related Content

Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry

Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.

Study evaluates polygenic risk score for prostate cancer risk prediction

Researchers identified 9 novel susceptibility loci for prostate cancer, 7 of which were substantially more prevalent in patients of African ancestry.

March 18th 2023

FDA approval sought for niraparib/abiraterone tablet for BRCA+ mCRPC

“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.

March 1st 2023

UnitedHealthcare will cover Genomic Prostate Score test

The application is supported by findings from the phase 3 MAGNITUDE study.

February 16th 2023

Diagnostics companies enter agreement to expand access to blood-based IsoPSA test

The GPS test uses a 17-gene signature to predict disease aggressiveness and help guide treatment decisions for patients with localized prostate cancer.